UAB researchers leading way on drug regimen battling cystic fibrosis

A triple combination drug has been shown to be effective in improving lung function for the majority of patients with cystic fibrosis.   The new therapy can provide therapeutic benefits for 90 percent of all patients with the disease, according to findings published in the New England Journal of Medicine. Researchers from UAB report the medication, which combines an experimental compound known as VX-659 with two existing medicati ons, tezacaftor and ivacaftor, improved lung function by more than…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news